Laurie Appleby MS, APRN, BCNurse Practitioner, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Laurie Appleby, APRN, BC, is a nurse practitioner with the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston. She provides direct oncologic care to patients with genitourinary cancers, including symptom management and telephone triage, and participates in the evaluation and management of patients enrolled in research protocols.
She received her nursing diploma from the Faulkner Hospital School of Nursing in Boston, her BSN from Northeastern University in Boston, and her MS in primary care nursing from Simmons College in Boston.
Ms. Appleby has made many presentations at seminars and symposia on the care of patients with renal cell carcinoma and management of side effects of targeted therapies. Her publications include: Management of Treatment Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence Based Practice and Best Practices. (Hematol Oncol Clin North Am. 2011;25:893-915).
Ms. Appleby is a member of the Oncology Nursing Society, the Nurse Advisory Board of the Kidney Cancer Association, and the Educational Program Advisory Committee (EPAC) of the National Comprehensive Cancer Network (NCCN).
Nurse Practitioner, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
BSN: Northeastern University, Boston, Massachusetts
MS (primary care nursing): Simmons College, Boston, Massachusetts
Recent Contributions to PracticeUpdate:
- ASCO 2016: Laurie Appleby’s Abstract Recommendations—Renal Cell Carcinoma
- Neurological, Respiratory, Musculoskeletal, Cardiac, and Ocular Side-Effects of Anti-PD-1 Therapy
- Managing the Side Effects Associated With Immune Checkpoint Inhibitors in the Treatment of RCC
- Fatigue, Mucositis, Hand–Foot Syndrome, and Dysgeusia in Treatment of Advanced Renal Cell Carcinoma
- 2015 Top Stories in Renal Cell Carcinoma: Immunotherapy
- Cardiovascular Toxicities in RCC
- IKCS 2015: How High Is Too High? Dose-Escalation Schemas in Patients With mRCC
- IKCS 2015: mRCC Tumor Burden Reduced With TKI Dose Escalation
- Cardiovascular Toxicity After Sorafenib or Sunitinib Therapy in Older Patients With Advanced Renal Cell Carcinoma
- ECC 2015: Recommendations From Laurie Appleby, APRN, BC